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Pancreatic adenocarcinoma is the fourth leading cause of 
cancer death in men and women in the United States and 
has  the  lowest  survival  rate  for  any  solid  cancer.  Over 
42,000 individuals are diagnosed with pancreatic cancer in 
the United States each year and over 35,000 will die of the 
disease  [1].  Similar  mortality  figures  are  reported  in 
Europe, with 1- and 5-year survival rates of only 15% and 
4%, respectively [2]. One important reason for this poor 
survival  is  that  about  85%  of  patients  present  with 
advanced disease, limiting our ability to treat the disease at 
an  early,  curable  stage  [3].  For  this  reason,  there  is 
considerable  interest  in  identifying  the  disease  in  its 
earliest stages, such as by screening high-risk individuals 
[4],  identifying  better  diagnostic  markers  of  early-stage 
disease [5], identifying familial and genetic risk factors that 
contribute  to  the  disease  [6],  and  ultimately  develop  ing 
risk prediction models to identify at-risk individuals [7].
Risk  factors  for  pancreatic  cancer  include  family 
history,  inheriting  deleterious  mutations  in  pancreatic 
cancer susceptibility genes (BRCA2, p16, STK11, PALB2 
and  PRSS1),  cigarette  smoking,  chronic  pancreatitis, 
long-standing  diabetes,  obesity,  Helicobacter  pylori 
infection and occupational exposures [8]. However, these 
factors  do  not  fully  account  for  the  prevalence  of 
pancreatic cancer. Furthermore, it is unclear how some of 
these  risk  factors  mediate  pancreatic  cancer  risk.  An 
association between non-O blood group and pancreatic 
cancer was first identified in the 1960s, but it has been 
underappreciated  as  a  risk  factor  despite  the  fact  that 
other studies found similar associations with gastric and 
other  cancers  [9-11].  Recently,  several  studies  have 
reported  a  significant  association  between  the  ABO 
blood group and pancreatic cancer risk [12-15].
ABO blood group and pancreatic cancer
The  Panscan  consortium  (which  consists  of  the  Pan-
creatic  Cancer  Cohort  Consortia  and  the  Pancreatic 
Cancer  Case-Control  Consortia  (Panc4))  performed  a 
genome-wide  association  study  (GWAS)  with  approxi-
mately 550,000 single nucleotide polymorphisms (SNPs) 
comparing 1,896 individuals with pancreatic cancer and 
1,939 controls ascertained from 12 cohort studies and the 
Mayo clinic case-control study (PanScanI) [14]. The SNP 
variants  that  provided  the  strongest  evidence  of 
association were then validated in an independent set of 
2,457 cases and 2,654 controls from eight case-control 
studies.  In  this  work,  several  common  variants  at  the 
ABO blood group locus showed significant evidence of 
association with pancreatic cancer in the combined data 
[14]. Among individuals of European ancestry, the SNP 
rs505992, located within the first intron of the ABO gene, 
was  strongly  associated  with  pancreatic  cancer 
(multiplicative  per-allele  odds  ratio  (OR)  1.20,  95% 
confidence interval (CI) 1.12 to 1.28, P = 5.37 × 10-8). This 
SNP is in complete linkage disequili  brium with, and is 
thereby  perfectly  correlated  with,  the  O/non-O  blood 
group variant.
The  ABO  system  was  first  described  by  Karl  Land-
steiner in 1900, and the ABO gene was cloned in 1990 
[16]. The ABO gene encodes glycosyltransferase enzymes 
that  transfer  specific  sugar  residues  to  the  H  antigen. 
There are three variant alleles (A, B and O), which encode 
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the  enzyme  α1R3  N-acetylgalactosaminyltransferase, 
which attaches N-acetylgalactosamine to the H antigen to 
form the A antigen. The B allele encodes α1R3 galacto  syl-
transferase, which attaches d-galactose, and the O allele 
encodes  a  non-functional  glycosyltransferase  and  thus 
the H antigen remains unmodified.
The  association  between  ABO  genotypes  and  pan-
creatic cancer reported by PanScan [14] was supported 
by  Wolpin  et  al.  [12],  who  identified  an  association 
between ABO serotypes and pancreatic cancer risk. They 
used two large prospective cohort studies (the Nurses’ 
Health Study and Health Professionals Follow-up Study) 
with 107,503 participants [12]. Cox proportional hazards 
model, adjusted for age, tobacco use, body mass index, 
physical  activity  and  history  of  diabetes  mellitus,  was 
used to calculate hazard ratios for pancreatic cancer by 
ABO  blood  type.  Compared  with  individuals  of  O 
serotype, individuals with blood group A, AB or B had a 
significantly increased rate of pancreatic cancer (Table 1).
To examine this association further, Wolpin et al. [12] 
then used the SNP data generated from the 12 cohort 
studies included in full PanScan GWAS to derive ABO 
genotypes (OO, AO, AA, AB, BO and BB) and ABO sero-
types (A, B, AB and O) and then examined the association 
of these two measures with pancreatic cancer risk [13]. 
Patients  with  pancreatic  cancer  were  compared  with 
controls without pancreatic cancer and matched for year 
of birth, gender, race/ethnicity and source of DNA, and 
four of the cohorts were matched for smoking status and 
baseline age. This analysis further supported their earlier 
findings: compared with individuals of blood group O, 
the  odds  of  developing  pancreatic  cancer  were  signifi-
cantly higher for individuals with blood group A, AB or 
B. The analyses also provided important information on 
the influence of genotype: individuals with AA, BB or AB 
genotype were at higher risk of pancreatic cancer than 
individuals  with  AO  or  BO  genotype  (Table  2).  The 
authors estimated that inheritance of non-O blood group 
accounted for 19.5% of all pancreatic cancer in indivi-
duals of European ancestry.
The  mechanism(s)  by  which  ABO  status  influences 
pancreatic cancer risk remains unclear. ABO antigens 
are found not only on the surface of red blood cells but 
also  on  the  surface  of  epithelial  cells  of  the  gastro-
intestinal, bronchopulmonary and urogenital tracts [17]. 
ABO blood group is associated with differences in several 
circulating inflammatory, infectious and vascular media-
tors,  and  therefore  chronic  inflammation  has  been 
suggested as a potential mechanism for the association 
between ABO blood group and cancer risk. On the other 
hand, loss of expression of ABO blood group has been 
described  in  some  pancreatic  cancers  and  a  systemic 
mechanism by which ABO blood groups predispose to 
pancreatic cancer would not be expected to require loss 
of expression of ABO in pancreatic cancers [9,18]. Also, if 
an inflammatory modifier role of ABO is causal in cancer 
development,  then  ABO  should  be  important  in  the 
develop  ment of numerous inflammation-mediated cancers, 
such as esophageal or gall-bladder cancer or colitis-asso-
ciated colorectal cancer, but no such association has been 
found  yet  [19].  The  association  between  ABO  and  a 
limited  number  of  cancers  and  evidence  for  loss  of 
expres  sion during tumor develop  ment implicate a tumor 
suppressor  role  for  blood  groups  A  and  B  in  cancer 
development.  Further  studies  to  better  elucidate  the 
mechanism by which ABO mediates cancer susceptibility 
are needed to fully understand this association.
Other genomic associations with pancreatic cancer
Recently, the PanScan consortium conducted a second 
GWAS  (PanScanII)  in  which  they  genotyped  approxi-
mately  620,000  SNPs  in  an  additional  1,955  cases  and 
1,955  controls  [15]  from  the  same  eight  case-control 
studies  used  for  replication  of  top  loci  in  the  original 
GWAS [14]. SNPs from the two studies were combined, 
resulting  in  data  on  approximately  550,000  SNPs  from 
3,851  individuals  with  pancreatic  cancer  and  3,934 
controls. Analysis of these combined regions identified 
Table 1. Hazard ratios for risk of pancreatic cancer by 
blood group 
  Hazard ratio relative  95% confidence 
Serotype  to O serotype  interval
A  1.32  1.02-1.72
AB  1.51  1.02-2.23
B  1.72  1.25-2.38
Values were calculated using the Cox proportional hazard model by Wolpin et 
al. [13] using data from the Nurses’ Health Study and the Health Professionals 
Follow-up Study.
Table 2. Odds ratios for risk of pancreatic cancer by blood 
group and ABO genotype
  Odds ratio relative to  95% confidence 
  O serotype or OO genotype  interval
Serotype
A  1.38  1.18-1.62
AB  1.47  1.07-2.02
B  1.53  1.21-1.92
Genotype
AA  1.61  1.22-2.18
BB  2.42  1.28-4.57
AB  1.47  1.07-2.02
AO  1.33  1.13-1.58
BO  1.45  1.14-1.85
Reproduced from Wolpin et al. [13].
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1q32.1 and 5p15.33 associated with an increased risk of 
pancreatic cancer. The locus on 13q22.1 was associated 
with SNP rs9543325, in a non-genic region between the 
transcription  factor  genes  KLF5  and  KLF12,  which 
regulate cell growth and transformation. Five SNPs were 
closely associated with the nuclear receptor family gene 
NR5A2 on 1q32.1, whose product is known to interact 
with  β-catenin.  The  strongest  SNP  was  rs3790844 
(P = 2.45 × 10−10, per-allele OR 0.77, 95% CI 0.71 to 0.84). 
A third locus marked by rs401681 (P = 3.66 × 10−7, per-
allele  OR  1.19,  95%  CI  1.11  to  1.27)  was  identified  on 
chromosome 5p15.33, within intron 13 of CLPTM1L and 
close to the telomerase reverse transcriptase gene, hTERT.
Although not much is known yet about the potential 
role  of  NR5A2,  KLF5  and  KLF12  in  pancreatic  cancer 
susceptibility,  the  hTERT-CLPTM1L  locus  has  been 
previously  implicated  as  a  cancer  susceptibility  gene 
[20-24]. Another SNP in this locus, rs4635969, ranked 
12th  most  significant  in  the  PanScan  GWAS,  with 
P = 1.05 × 10-6, just short of genome-wide significance. 
Although CLPTM1L is upregulated in cisplatin-resistant 
cell lines and may have a role in apoptosis, because of the 
importance  of  telomeres  in  cancer  susceptibility  it  is 
suspected  that  these  variants  are  more  likely  to  be 
important  for  their  influence  on  hTERT  and  telomere 
length and function rather than on CLPTM1L.
hTERT  is  expressed  in  approximately  90%  of  human 
cancers and is essential for maintaining telomere ends. 
Germline mutations in hTERT can cause acute myeloid 
leukemia and aplastic anemia, and rare variants in hTERT 
cause inherited bone marrow failure [25-27]. Telomere 
length has a strong inherited component [28]. Telomeres 
are made up of DNA repeat sequences (TTAGGG) and 
telomere  binding  proteins  [29]  that  prevent  fusion 
between ends of chromosomes. Telomeric fusions occur 
at  critically  shortened  telomeres  and  lead  to  ring  and 
dicentric  chromosomes  that  form  anaphase  bridges. 
Breakage of anaphase bridges generates highly recom  bi-
no  genic  free  DNA  ends,  fusion  of  broken  ends  and 
chromosomal rearrangements that can be self-perpetu-
ating  and  are  typical  of  many  cancers  [30].  Telomere 
shortening will cause senescence unless pathways such as 
p53  are  overcome  [31],  and  neoplastic  clones  later 
express  hTERT  and  telomerase  for  cellular  immortali-
zation  [32-38].  Pancreatic  adenocarcinomas  have  very 
short  telomeres  [35],  complex  karyotypes,  numerous 
chromosomal  abnormalities  and  high  fractional  allelic 
losses [36,37]. The T allele of rs401681 is associated with 
increased risk of pancreatic cancer and melanoma [23], 
but the C allele is associated with an increased risk of 
lung,  prostate,  basal  cell  and  bladder  cancers  [20-23]. 
Initial attempts to find a correlation between the hTERT 
variant rs401681 with telomere length were inconclusive, 
perhaps because other factors such as age, sex, smoking 
and exercise influence telomere length [38-40].
Implications for research and therapy
One challenge with GWAS discoveries has been deter-
mining how these findings could benefit clinical practice. 
Generally,  GWAS  discoveries  have  provided  important 
clues  to  disease  mechanisms  that  will  hopefully  even-
tually have an impact on clinical management of disease. 
The small magnitude of risk estimates attributable to an 
individual  disease-associated  SNP  have  not  generally 
been large enough to provide immediate clinical benefits 
in areas such as risk prediction [41,42]. Studies are now 
underway  to  determine  whether  pancreatic  cancer 
GWAS alleles influence pancreatic cancer prognosis and 
response to therapy.
In summary, the results of the first pancreatic cancer 
GWASs  have  added  to  our  knowledge  of  genetic  loci 
associated with pancreatic cancer. The PanScan GWAS 
was a robust study that included a large number of cases 
and controls, many of whom were originally enrolled in 
large,  well-designed  prospective  studies.  At  the  same 
time, these first GWASs [15,16] were powered to detect 
alleles  with  relatively  large  effects,  and  alleles  with 
moderate to small effect on pancreatic cancer risk may 
have been overlooked. Further studies are now needed to 
investigate  the  mechanisms  by  which  the  association 
between ABO blood group antigens and variants in other 
loci, such as the hTERT locus, contribute to pancreatic 
cancer susceptibility. Given the early success of the first 
pancreatic cancer GWAS, larger association studies are 
likely  to  provide  additional  insights  into  pancreatic 
cancer susceptibility. GWASs are very useful for identify-
ing  common  low-penetrance  alleles  that  contribute  to 
disease susceptibility [43-45], and diseases that have gone 
through  several  rounds  of  GWASs  and  post-GWAS 
validation continue to yield important new findings and 
to  refine  the  significance  of  earlier  findings  [46]. 
Understanding the genetic and biological mechanisms of 
pancreatic cancer will eventually improve our ability to 
diagnose and treat this deadly disease.
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